Nir Paran

4.8k total citations · 3 hit papers
58 papers, 2.0k citations indexed

About

Nir Paran is a scholar working on Virology, Epidemiology and Infectious Diseases. According to data from OpenAlex, Nir Paran has authored 58 papers receiving a total of 2.0k indexed citations (citations by other indexed papers that have themselves been cited), including 27 papers in Virology, 25 papers in Epidemiology and 23 papers in Infectious Diseases. Recurrent topics in Nir Paran's work include Poxvirus research and outbreaks (24 papers), SARS-CoV-2 and COVID-19 Research (17 papers) and Herpesvirus Infections and Treatments (14 papers). Nir Paran is often cited by papers focused on Poxvirus research and outbreaks (24 papers), SARS-CoV-2 and COVID-19 Research (17 papers) and Herpesvirus Infections and Treatments (14 papers). Nir Paran collaborates with scholars based in Israel, United States and Japan. Nir Paran's co-authors include Sharon Melamed, Tomer Israely, Hadas Tamir, Yfat Yahalom-Ronen, Ofir Israeli, Hagit Achdout, Shay Weiss, Yosef Shaul, Noam Erez and Adi Beth-Din and has published in prestigious journals such as Nature, Proceedings of the National Academy of Sciences and Journal of Biological Chemistry.

In The Last Decade

Nir Paran

57 papers receiving 2.0k citations

Hit Papers

The coding capacity of SARS-CoV-2 2019 2026 2021 2023 2020 2019 2021 100 200 300

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Nir Paran Israel 24 962 772 768 659 308 58 2.0k
Sharon Melamed Israel 16 609 0.6× 534 0.7× 504 0.7× 520 0.8× 173 0.6× 35 1.3k
Zhi Hong United States 22 815 0.8× 921 1.2× 996 1.3× 309 0.5× 157 0.5× 34 2.6k
Ruben M. Markosyan United States 19 585 0.6× 624 0.8× 549 0.7× 797 1.2× 517 1.7× 24 1.7k
Shay Weiss Israel 16 863 0.9× 521 0.7× 333 0.4× 349 0.5× 199 0.6× 53 1.5k
Jing Jin United States 24 691 0.7× 630 0.8× 839 1.1× 555 0.8× 479 1.6× 65 2.3k
William R. Gallaher United States 19 728 0.8× 792 1.0× 577 0.8× 751 1.1× 384 1.2× 36 2.0k
Eleftherios Michailidis United States 24 691 0.7× 1.2k 1.5× 726 0.9× 531 0.8× 252 0.8× 46 2.1k
Karin J. Metzner Switzerland 27 640 0.7× 1.2k 1.6× 365 0.5× 1.5k 2.2× 311 1.0× 102 2.3k
Carol D. Weiss United States 27 669 0.7× 1.2k 1.6× 775 1.0× 1.6k 2.4× 756 2.5× 65 2.6k
Dennis M. Lambert United States 15 640 0.7× 1.2k 1.5× 616 0.8× 1.3k 1.9× 383 1.2× 27 2.3k

Countries citing papers authored by Nir Paran

Since Specialization
Citations

This map shows the geographic impact of Nir Paran's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Nir Paran with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Nir Paran more than expected).

Fields of papers citing papers by Nir Paran

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Nir Paran. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Nir Paran. The network helps show where Nir Paran may publish in the future.

Co-authorship network of co-authors of Nir Paran

This figure shows the co-authorship network connecting the top 25 collaborators of Nir Paran. A scholar is included among the top collaborators of Nir Paran based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Nir Paran. Nir Paran is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Wirblich, Christoph, et al.. (2024). Toward the Development of a Pan-Lyssavirus Vaccine. Viruses. 16(7). 1107–1107. 2 indexed citations
2.
Avraham, Roy, Hagit Achdout, Noam Erez, et al.. (2023). Antiviral activity of glucosylceramide synthase inhibitors in alphavirus infection of the central nervous system. Brain Communications. 5(3). fcad086–fcad086. 6 indexed citations
3.
Cohen, Dani, Marina Izak, Evgeniy Stoyanov, et al.. (2023). Predictors of reinfection with pre-Omicron and Omicron variants of concern among individuals who recovered from COVID-19 in the first year of the pandemic. International Journal of Infectious Diseases. 132. 72–79. 9 indexed citations
4.
Yahalom-Ronen, Yfat, Hadas Tamir, Sharon Melamed, et al.. (2023). VSV-ΔG-Spike Candidate Vaccine Induces Protective Immunity and Protects K18-hACE2 Mice against SARS-CoV-2 Variants. Viruses. 15(6). 1364–1364. 2 indexed citations
5.
Fisher, Tal, Krishna Narayanan, Makoto Kuroda, et al.. (2022). Parsing the role of NSP1 in SARS-CoV-2 infection. Cell Reports. 39(11). 110954–110954. 43 indexed citations
6.
Israeli, Ofir, Ohad Shifman, Shirley Lazar, et al.. (2022). Rapid Amplicon Nanopore Sequencing (RANS) for the Differential Diagnosis of Monkeypox Virus and Other Vesicle-Forming Pathogens. Viruses. 14(8). 1817–1817. 15 indexed citations
7.
Elia, Uri, Srinivas Ramishetti, Ronit Rosenfeld, et al.. (2021). Design of SARS-CoV-2 hFc-Conjugated Receptor-Binding Domain mRNA Vaccine Delivered via Lipid Nanoparticles. ACS Nano. 15(6). 9627–9637. 84 indexed citations
8.
Finkel, Yaara, Aharon Nachshon, Roni Winkler, et al.. (2021). SARS-CoV-2 uses a multipronged strategy to impede host protein synthesis. Nature. 594(7862). 240–245. 160 indexed citations breakdown →
9.
Finkel, Yaara, Orel Mizrahi, Aharon Nachshon, et al.. (2020). The coding capacity of SARS-CoV-2. Nature. 589(7840). 125–130. 382 indexed citations breakdown →
10.
Erez, Noam, Hagit Achdout, Elad Milrot, et al.. (2019). Diagnosis of Imported Monkeypox, Israel, 2018. Emerging infectious diseases. 25(5). 980–983. 302 indexed citations breakdown →
11.
Achdout, Hagit, Shlomo Lustig, Tomer Israely, et al.. (2017). Induction, treatment and prevention of eczema vaccinatum in atopic dermatitis mouse models. Vaccine. 35(33). 4245–4254. 9 indexed citations
12.
Israely, Tomer, Sharon Melamed, Hagit Achdout, et al.. (2014). TLR3 and TLR9 Agonists Improve Postexposure Vaccination Efficacy of Live Smallpox Vaccines. PLoS ONE. 9(10). e110545–e110545. 15 indexed citations
14.
Bengali, Zain, Panayampalli S. Satheshkumar, Zhilong Yang, et al.. (2011). Drosophila S2 Cells Are Non-Permissive for Vaccinia Virus DNA Replication Following Entry via Low pH-Dependent Endocytosis and Early Transcription. PLoS ONE. 6(2). e17248–e17248. 24 indexed citations
15.
Levy, Orly, Nir Paran, Avi Keysary, et al.. (2010). Establishment of cell-based reporter system for diagnosis of poxvirus infection. Journal of Virological Methods. 167(1). 23–30. 8 indexed citations
18.
Eyal, Osnat, Udy Olshevsky, Shlomo Lustig, et al.. (2005). Development of a tissue-culture-based enzyme-immunoassay method for the quantitation of anti-vaccinia-neutralizing antibodies in human sera. Journal of Virological Methods. 130(1-2). 15–21. 16 indexed citations
19.
Cooper, Arik, Nir Paran, & Yosef Shaul. (2003). The earliest steps in hepatitis B virus infection. Biochimica et Biophysica Acta (BBA) - Biomembranes. 1614(1). 89–96. 26 indexed citations
20.
Paran, Nir, Arik Cooper, & Yosef Shaul. (2003). Interaction of hepatitis B virus with cells. Reviews in Medical Virology. 13(3). 137–143. 12 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026